23451-96-9

Usage

Uses

Used in Scientific Research:
5-Methyl-2-aminobenzenethiol is used as a reagent in biochemical reactions, contributing to the advancement of scientific knowledge and understanding of various biological processes.
Used in Chemical Industry:
5-Methyl-2-aminobenzenethiol is used in the production of various products such as dyes, pharmaceuticals, and polymers. Its physical characteristics and chemical reactivity can vary depending on factors like temperature and pressure, making it a versatile compound for different applications in the chemical industry.

InChI:InChI=1/C7H9NS/c1-5-2-3-6(8)7(9)4-5/h2-4,9H,8H2,1H3

Upstream product

• 2536-91-6 6-methylbenzothiazol-2-ylamine 
• 10205-58-0 6-methyl-2-phenyl-1,3-benzothiazole 
• 92-36-4 2-(4-aminophenyl)-6-methyl-1,3-benzothiazole 
• 31183-91-2 2-[(2-amino-5-methylphenyl)dithio]-4-methylphenylamine 
• 2942-15-6 6-methylbenzothiazole 
• 112308-05-1 S-benzoyl-N-dimethylcarbamoyl-2-amino-5-methylthiophenol 
• 1503-92-0 N-p-tolylbenzohydroxamic acid 
• 112308-08-4 N-benzoyl-2-amino-5-methylthiophenol 
• 112308-03-9 N-benzoyl-S-dimethylcarbamoyl-2-amino-5-dimethylthiophenol 
• 112308-06-2 N,S-dibenzoyl-2-amino-5-methylthiophenol 
• 106-49-0 p-toluidine 
• 622-52-6 p-methylphenylthiourea 
• 540-23-8 p-toluidine hydrochloride 

Downstream Products

• 2941-71-1 2,6-dimethylbenzothiazole 
• 10205-58-0 6-methyl-2-phenyl-1,3-benzothiazole 
• 488722-57-2 6-methyl-2-(4'-nitrophenyl)-1,3-benzothiazole 
• 2942-15-6 6-methylbenzothiazole 
• 31183-91-2 2-[(2-amino-5-methylphenyl)dithio]-4-methylphenylamine 
• 37764-09-3 2-amino-5-bromo-N-(2-mercapto-4-methyl-phenyl)-benzamide 
• 54469-51-1 1-(6-methyl-benzothiazol-2-yl)-ethanol 
• 60598-39-2 6-anilino-9-methyl-benzo[a]phenothiazin-5-one 
• 76273-51-3 ethyl 3,7-dimethyl-4H-benzo[b][1,4]thiazine-2-carboxylate 
• 88016-71-1 2-(2'-Hydroxyphenyl)-6-methyl-benzthiazol 
• 76273-52-4 1-(3,7-dimethyl-4H-benzo[b][1,4]thiazin-2-yl)ethanone 
• 93075-39-9 (3,7-Dimethyl-4H-benzo[1,4]thiazin-2-yl)-phenyl-methanone 
• 101078-74-4 2-<4-(bromomethyl)phenyl>-6-methylbenzothiazole 
• 98120-08-2 2-(p-chlorobenzoyl)-3,7-dimethyl-4H-1,4-benzothiazine 

Relevant academic research and scientific papers

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist

Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound27h(designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors.27halso potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition,27hdemonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2= 4.98 h). Significantly, oral administration of compound27hachieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound27hmay serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.

Facile syntheses of 3-trifluoromethylthio substituted thioflavones and benzothiophenes via the radical cyclization

3-CF3S substituted thioflavones and benzothiophenes were achieved via the reactions of AgSCF3 with methylthiolated alkynones and alkynylthioanisoles, respectively, promoted by persulfate. This protocol possesses good functional group tolerance and high yields. Mechanistic studies suggested that a classic two-step radical process was involved, which includes addition of CF3S radical to triple bond and cyclization with SMe moiety.

A Novel Difluoroacetic Acid Derivatives Compound, and Composition Comprising the Same

The present invention relates to a novel difluoroacetic acid derivative compound and a composition for various uses containing the same, wherein the difluoroacetic acid derivative compound can not only act as an agonist activating one among PPARandalpha;, andbeta; or andgamma;, but also can exhibit double efficacy or triple efficacy. Therefore, the difluoroacetic acid derivative compound can more effectively prevent, alleviate or treat metabolic diseases in which PPARs involves, and further exhibits whitening and wrinkle alleviation activity, and anti-inflammatory and antioxidant effects, thereby being able to be usefully utilized as various compositions.COPYRIGHT KIPO 2020

Convenient and efficient synthesis of novel 11: H -benzo[5,6][1,4]thiazino[3,4- a] isoindol-11-ones derived from 2-bromo-(2/3-substitutedphenyl)-1 H -indene-1,3(2 H)-diones

An unprecedented formation of 11H-benzo[5,6][1,4]thiazino[3,4-a]isoindol-11-ones through a one-step reaction of differently substituted 2-aminobenzenethiols and 2-bromo-(2/3-substitutedphenyl)-1H-indene-1,3(2H)-diones in freshly dried ethanol under reflux conditions has been investigated. This unique transformation probably occurs through an initial nucleophilic substitution followed by ring opening and subsequent intramolecular cyclization. The structures of all the synthesized benzo[1,4]thiazino isoindolinones were established by FTIR, 1H NMR, 13C NMR, HRMS, and X-ray crystallographic analysis. This approach was found to be simple and convenient and provides several advantages such as substantial atom economy, short reaction time and operational simplicity.

Novel SIRT 1 activator and medical use thereof

The present invention relates to a SIRT 1 activator and medical uses thereof. In the present invention, a novel SIRT 1 activator compound based on a benzo[d]thiazole skeleton, a crystalline form thereof, a hydrate thereof or a salt thereof is prepared, and effect on alleviating obesity, insulin resistance and dyslipidemia, alleviating fatty liver, preventing cell aging, preventing oxidative stress and extending of life of yeast. Therefore, the novel SIRT 1 activator compound having the above effects can be used for a pharmaceutical composition for therapeutic use for preventing or treating metabolic diseases including obesity, diabetes mellitus, dyslipidemia and the like and liver diseases including alcoholic or non-alcoholic fatty liver, fatty liver diseases and the like, and a health food composition for alleviating cell aging or prolonging the life span, and the like.COPYRIGHT KIPO 2018

Synthesis of Indane-Based 1,5-Benzothiazepines Derived from 3-Phenyl-2,3-dihydro-1H-inden-1-one and Antimicrobial Studies Thereof

In the present study, a series of 20 indane-based 1,5-benzothiazepines (5a–t) has been prepared derived from 3-phenyl-2,3-dihydro-1H-inden-1-one (1). All the synthesized 1,5-benzothiazepines (5a–t) were screened for their in vitro antimicrobial activities against four bacteria [Bacillus subtilis (MTCC 441), Staphylococcus epidermidis (MTCC 6880), Escherichia coli (MTCC 1652), and Pseudomonas aeruginosa (MTCC 424)] and two fungi [Candida albicans (MTCC 227) and Aspergillus niger (MTCC 8189)]. Among all the tested derivatives, 5n and 5o against E.?coli displayed more inhibitory activity than that of the reference drug, ciprofloxacin, while the derivatives 5c, 5m–o, 5s, and 5t against C.?albicans, and 5d, 5e, 5n, 5o, 5s, and 5t against A.?niger were found to be more potent than the standard drug, that is, fluconazole.

Natural Product-Mimetic Scaffolds with Privileged Heterocyclic Systems: Design, Synthesis, and Evaluation of Antioxidant Activity of Quinazoquinobenzothiazinones

(Chemical Equation Presented) Structurally diverse quinazolinoquinolinobenzothiazinones based on rutaecarpine structural framework with hybrid structural features of three medicinally privileged heterocyclic systems has been synthesized as natural product-mimetic scaffolds involving the use of multi-step reaction sequences. The synthesized quinazolinoquinolinobenzothiazinones have been evaluated for their antioxidant and radical scavenging activities.

Efficient and convenient synthesis, characterization, and antimicrobial evaluation of some new tetracyclic 1,4-benzothiazines

In the present study, 20 new tetracyclic 1,4-benzothiazines (4a-4 t) were conveniently synthesized in good yields and characterized by different spectral and physical techniques. The in vitro antimicrobial evaluation of the synthesized benzothiazine derivatives was performed by serial dilution against two Gram-positive bacteria [Bacillus subtilis (MTCC 441) and Staphylococcus epidermidis (MTCC 6880)], two Gram-negative bacteria [Escherichia coli (MTCC 1652) and Pseudomonas aeruginosa (MTCC 424)], and two fungal strains [Candida albicans (MTCC 227) and Aspergillus Niger (MTCC 8189)]. The derivatives 4 l and 4 t were found to be more potent than standard drug, i.e., fluconazole, against A. Niger and C. albicans, respectively.

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

The flocculated acryloyldimethyltauric molecule ligand

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.